^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Senl 1904A

    i
    Other names: Senl 1904A, Senl_1904A CD19 CAR-T cell therapy
    Associations

    News

    Trials
    Company:
    SenlangBio
    Drug class:
    CD19-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    over3years
    Senl_1904A and Senl_1904B Chimeric Antigen Receptor （CAR） T-Cell in the Treatment of r/ r Acute B Lymphocytic Leukemia (clinicaltrials.gov)
    P1, N=20, Active, not recruiting, Hebei Senlang Biotechnology Inc., Ltd. | Recruiting --> Active, not recruiting | Trial completion date: Jan 2020 --> Jan 2022 | Trial primary completion date: Sep 2019 --> Sep 2021
    Clinical • Enrollment closed • Trial completion date • Trial primary completion date • CAR T-Cell Therapy
    |
    CD19 (CD19 Molecule)
    |
    CD19 positive
    |
    Senl 1904A • Senl 1904B